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Abstract
Drug resistance, mediated by various mechanisms, plays a crucial role in the failure of the drug-based treatment of various
infectious diseases. As a result, these infectious diseases re-emerge rapidly and cause many victims every year. Another serious
threat is imposed by the development of multidrug resistance (MDR) in eukaryotic (tumor) cells, where many different drugs
fail to perform their therapeutic function. One of the causes of the occurrence of MDR in these cells is the action of
transmembrane transport proteins that catalyze the active extrusion of a large number of structurally and functionally
unrelated compounds out of the cell. The mode of action of these MDR transporters and their apparent lack of substrate
specificity is poorly understood and has been subject to many speculations. In this review we will summarize our current
knowledge about the occurrence, mechanism and molecular basis of (multi-)drug resistance especially as found in bacteria.
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1. Introduction: the drug wars
Most organisms are in constant contact with other
species from various kingdoms. A close physical as-
sociation can be bene¢cial or even crucial for the
organisms involved, for example when interspecies
transfer of essential compounds (e.g. nutrients, vita-
mins, etc.) occurs or when preferred habitats are
provided. On the other hand, occupation of the
same habitats can be disadvantageous when the or-
ganisms have to compete for essential compounds or
when the habitat is negatively in£uenced by one of
the organisms, for example by the excretion of toxic
compounds by one of the organisms. Millions of
years of evolution have resulted in the development
of various defence strategies leading to a well-bal-
anced co-existence of di¡erent species in nature.
Nevertheless, such a balance can easily be disturbed,
for instance, by introducing hostile species into the
habitat. Also for humans this situation happens as a
result of increased intercontinental tra¤c. Natural
defence mechanisms may also fail in situations of
bad hygienic and physical conditions, for example,
as a result of prolonged starvation and/or environ-
mental pollution. In particular, pathogenic organ-
isms can become life threatening to humans with a
suppressed immune system, like AIDS patients and
patients that have been subject to intensive surgery
or organ transplantation. In the worst case this can
eventually reach epidemic forms and threaten whole
populations.
The introduction of antibiotics in the 1940s gave a
completely new prospect to medical science and the
treatment of infectious diseases. A broad variety of
drugs were discovered or developed which were ac-
tive against several infectious organisms. At present,
drug-based treatments form the major strategy
against infectious diseases of parasitic, fungal as
well as bacterial origin. In addition, cytotoxic drugs
have been successfully used in the chemotherapeutic
treatment of various cancers.
The widespread, and sometimes uncontrolled, use
of these drugs has led to the emergence of (new)
defence mechanisms which, at present, form the
major drawback of the drug-based treatment of in-
fectious diseases and cancers. This has led in the
1990s to the publication of several reports and public
warnings, in which attention was asked for the
increasing numbers of resistant organisms and the
re-emergence of once easily treatable diseases like
tuberculosis [1,2]. Most strikingly, resistance of
these organisms was not restricted to the drugs
(or analogs) used in the treatment but also involved
several structurally and functionally unrelated com-
pounds, confronting medical science with a new
problem. This phenomenon, which was termed
multidrug resistance (MDR), can be caused by
various mechanisms and is known to play an impor-
tant role in drug resistance of a broad range of
pathogenic bacteria [3^5], parasitic protozoa like
Plasmodium spp., Entamoeba spp., and Leishmania
spp. [6], and tumor cells [7,8]. All together, these
diseases are responsible for millions of deaths yearly.
Several reports have also indicated the clinical
importance of drug resistance in the treatment of
meticillin-resistant Staphylococcus aureus [9^11],
Escherichia coli infections [12], and bacterial menin-
gitis [13]. Drug resistance is di¤cult to control
in hospital environments due to the limited num-
ber of e¡ective agents that are available. The ex-
pected increase in drug resistant bacteria in
the near future can have disastrous consequen-
ces for public health, if a solution is not quickly
found.
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2. Drug resistance mechanisms in bacteria
Many, if not all, organisms have developed several
resistance mechanisms in response to exposure to a
broad variety of toxic compounds, i.e. xenobiotics,
naturally occurring toxins as well as endogenous
metabolic end-products found in antibiotic produc-
ing species like Streptomyces spp. [14]. Di¡erent
mechanisms, including MDR and speci¢c drug
resistance (SDR), are known in bacteria which
can account for the protection against toxic com-
pounds.
These resistance mechanisms comprise: (i) the
enzymatic inactivation or degradation of drugs,
(ii) alterations of the drug target, (iii) prevention
of drug entry, and (iv) active extrusion of drugs.
The ¢rst three mechanisms have been extensively
reviewed (see special issue on antibiotic resistance,
Science, Vol. 264, 15 April 1994) and will only be
dealt with brie£y in this paper, whereas the drug
extrusion systems will form the main topic of this
review.
(i) Drug inactivation is the major mechanism of
resistance towards L-lactam antibiotics. Inactivation
of L-lactam antibiotics like penicillin is mediated by
penicillinases that catalyze the hydrolysis of the
L-lactam ring [15,16]. Other well-known enzymes
that cause drug inactivation are chloramphenicol
transferases [17] and aminoglycoside modifying en-
zymes [18].
(ii) Protection by alteration of the drug target(s)
may prevent the interaction and hence the toxicity
of antibiotics. These alterations comprise amino
acid substitutions, which decrease the a¤nity for
the drugs involved. Penicillin resistance can be
caused by alterations in the so-called penicillin bind-
ing proteins (PBPs) that form irreversible complexes
with penicillin, thereby inhibiting their role in pep-
tidoglycan synthesis [15]. Erythromycin and tetra-
cycline resistance can be mediated by covalent
modi¢cations of the ribosomes, which make them
less susceptible to the action of these antibiotics
[19,20].
(iii) In addition to the cell membrane as barrier for
drug entry, these compounds have to pass cell enve-
lope barriers such as the outer membrane in Gram-
negative bacteria. Gram-positive organisms are
equipped with a thick peptidoglycan layer which is
less e¡ective as a permeability barrier than the outer
membrane of the Gram-negative organisms. This is
re£ected in the overall higher sensitivity of Gram-
positive organisms to various toxic compounds
[21,22]. Alterations that in£uence the permeability
of these barriers, like the amount of outer membrane
porins and/or lipopolysaccharides in the outer mem-
brane, can therefore a¡ect the apparent resistance
against drugs [23]. The barrier function, however,
cannot prevent these drugs from exerting their toxic
action once they have entered the cell and additional
resistance mechanisms will be required to achieve
signi¢cant levels of drug resistance [4].
(iv) Active drug extrusion will lower the cytoplas-
mic drug concentration and hence will increase drug
resistance [24]. Several integral membrane proteins
have been characterized that mediate active drug ex-
trusion and at present they are recognized as the
major mechanism of MDR or SDR.
3. Active drug extrusion
Many anticarcinogenic drugs, including vinca al-
kaloids (vincristine, vinblastine), anthracyclines (dau-
norubicin, doxorubicin), actinomycin D and epipo-
dophillotoxins, and cytotoxic compounds like
colchicine, rhodamine and ethidium bromide (Fig.
1), are extruded from various types of cells [7,25].
Active drug extrusion as a mechanism of drug resist-
ance was ¢rst recognized in MDR tumor cells [26].
The MDR phenotype of Chinese hamster ovary cells
correlated with the overexpression of a 170^190 kDa
integral membrane protein termed P-glycoprotein
(`P' for permeability) or P-gp [27]. The general opin-
ion is that P-gp mediates the ATP dependent extru-
sion of drugs, thereby preventing intracellular drug
accumulation and concomitant cytotoxic e¡ects [28^
33]. In addition to P-gp, a number of other trans-
porters are characterized that mediate MDR in
mammalian cells, including the
multidrug resistance
associated protein (MRP) [34,35], a membrane po-
tential dependent MDR transporter OCT1 in rat
kidney [36], and an ATP dependent MDR activity
in lung carcinoma cells [37].
Bacterial antibiotic resistance resulting from drug
extrusion was ¢rst identi¢ed in tetracycline resistant
strains of E. coli [38], and was soon followed by the
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Fig. 1. Structural features of a number of typical MDR substrates.
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discovery of other bacterial drug [39^42] and heavy
metal transporters [43]. Subsequently, several resist-
ant strains were isolated by selection for growth on
single toxic compounds (e.g. tetraphenylphospho-
nium (TPP

), carbonyl cyanide m-chlorophenylhy-
drazone (CCCP), ethidium bromide and rhodamine
6G) that were cross-resistant to a number of unre-
lated drugs and hence were identi¢ed as MDR mu-
tants [40,42,44^47]. On the basis of bioenergetic and
structural criteria, the known drug transporters of
eukaryotes and prokaryotes are subdivided into (i)
ATP-binding cassette (ABC)-type transporters, and
(ii) secondary transporters.
3.1. ATP dependent drug transporters
Several drug extrusion systems utilize the free en-
ergy of ATP hydrolysis to drive drug extrusion and
belong to the class of primary transport systems. The
known ATP dependent drug transporters all belong
to the ABC superfamily [48], also known as tra¤c
ATPases [49]. The ABC transporter family includes
uptake and e¥ux systems from bacteria, lower eu-
karyotes as well as mammals [50^52] and are best
exempli¢ed by the mammalian MDR transporters.
Most bacterial ATP dependent drug extrusion sys-
tems are SDR transporters, such as Ard1 [53], TnrB
FEMSRE 593 31-10-97
Fig. 2. Structural organization of ABC transporters. Two transmembrane domains (TMD), each consisting of six putative membrane
spanning K-helical segments (depicted as ellipses) are present in the phospholipid bilayer. The nucleotide binding domains (NBD) are lo-
cated at the cytoplasmic surface of the membrane and contain the highly conserved ABC signature (ABC) and Walker A and B motifs
which are involved in ATP hydrolysis. The most conserved residues in these motifs are indicated.
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[54] and OleC plus OleB [55,56], which excrete of the
endogenous toxic metabolite antibiotic A201A, te-
tronasin and oleandomycin, respectively, and these
proteins are often referred to as `immunity' proteins
[57,58]. The SDR transporter DrrAB of Streptomy-
ces peucetius confers resistance to its secondary me-
tabolites daunorubicin and doxorubicin, which are
widely used as anticancer drugs and are well-known
MDR substrates [14].
Other bacterial primary SDR transporters are in-
volved in the extrusion of unfamiliar compounds like
bacitracin by Bacillus licheniformis, BCECF by Lac-
tococcus lactis [59], and tunicamycin by B. subtilis
[60,61]. The only bacterial ATP dependent MDR
transporter known to date is LmrA of L. lactis,
which shares both functional and structural homol-
ogy with P-glycoprotein [42,62].
3.1.1. Domain organization of P-glycoprotein
The predicted secondary structure of P-gp shows a
typical two times two domain organization, which
most likely has arisen from an internal gene duplica-
tion event [63]. It consists of two hydrophobic trans-
membrane domains with six putative transmembrane
K-helical segments (TMS) each, and two hydrophilic
domains containing the highly conserved ATP bind-
ing cassette, the major diagnostic feature of the ABC
superfamily (Fig. 2) [64,65]. The initial topology
model of P-gp was predicted on the basis of the
hydropathy pro¢le and the assumption that the hy-
drophilic domains, containing the nucleotide binding
domains, are located intracellularly (Fig. 3) [66]. This
model is supported by epitope mapping with speci¢c
monoclonal antibodies [67], analysis of the N-glyco-
sylation sites which are found in the ¢rst extracellu-
lar loop between TMS1 and 2 [68,69], and direction-
al labelling of single cysteine mutants [70].
Alternative models for the topology of P-gp have
been suggested on the basis of P-gp-PhoA fusions
constructed in the C-terminal half of MDR and ex-
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Fig. 3. Predicted secondary structure of the MDR-1 P-glycoprotein. P-glycoprotein is a single polypeptide consisting of 12 transmembrane
K-helical segments. Putative N-linked carbohydrates, located in the ¢rst extracellular loop, are indicated. The white asterisks indicate the
putative transmembrane K-helical segments that are thought to contribute to the transport pathway directly.
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pressed in E. coli. These studies revealed that the
hydrophobic stretch, original identi¢ed as TMS4, is
located in the aqueous space [71] and that TMS7
actually consists of two TMSs [72]. Expression of
P-gp, by in vitro translation in a cell free system
containing microsomal membranes, suggested that
TMS3 and 5 [73] and TMS8 and 10 [74] or TMS8
and 9 [75] reside in the aqueous phase rather than in
the membrane. It was also observed that the topol-
ogy of P-gp could be modulated by changing the
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Fig. 4. Alignment of the deduced amino acid sequences of a number of ABC-type MDR transporters. The amino acid sequence of the
lactococcal primary drug transporter LmrA (LLLmrA) was aligned with that of the amino-terminal halves of the MDR transporters from
human (HUMDR1N), mouse (MMMDR1N) and Caenorhabditis elegans (CEMdr1N). Putative transmembrane spanning K-helical seg-
ments are boxed and shown in bold-face. The conserved ABC signature (ABC) and the Walker A and B motifs are indicated.
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amino acid composition of the protein and by spe-
ci¢c cytoplasmic components, probably proteins, of
yet unknown origin [76]. Since these alternative mod-
els have been derived from in vitro studies or heter-
ologous expression systems, it remains to be estab-
lished how these models relate to the in vivo
situation.
Comparison of the domain organization of other
ABC transporters reveals a modular composition in
which each domain can be synthesized as a separate
polypeptide or fused to one or more other domains.
Moreover, there is quite some £exibility in the order
in which the domains appear in the single polypep-
tides [50]. For example, in P-gp the hydrophilic and
hydrophobic domains occur twice within the poly-
peptide, whereas these domains are found only
once in, for example, the lactococcal ATP dependent
MDR transporter LmrA, and in the hemolysin
transporter HlyB of E. coli. These transport proteins
function most likely as homodimers [62,77]. Alterna-
tively, the translocator portion of the oligopeptide
permease of S. typhimurium is composed of four sep-
arately encoded proteins [78]. The variable order in
which the domains appear in a single polypeptide is
exempli¢ed by P-gp and the yeast ABC transporter
Sts1, which have the nucleotide binding domains lo-
cated at the carboxy- and amino-termini, respectively
[79].
3.1.2. Structure-function relationships of the human
ABC transporter P-glycoprotein
Information about the structure-function relation-
ships within protein domains of homologous pro-
teins can be obtained from the analysis of chimeric
proteins, complementation studies, and analysis of
site directed mutants which were designed on the
basis of amino acid sequence alignments. An exam-
ple of such an alignment is given in Fig. 4 where the
amino acid sequence of LmrA is compared to that of
the amino-terminal halves of three di¡erent mamma-
lian MDR transporters. From this and other align-
ments it becomes apparent that amino acid conser-
vation is mainly found in the hydrophilic nucleotide
binding domains and much less pronounced in the
transmembrane domain. Unfortunately, the aligned
sequences of the di¡erent MDR transporters in gen-
eral provide little information for educated guesses
of important amino acid residues or regions in the
proteins. The selection of mutants with an altered
drug speci¢city might therefore be the strongest
(non-crystallographic) tool for ¢nding residues that
are critical for substrate binding.
Some surprising observations were made when
knock-out mutants were complemented in trans
with distantly related ABC transporter encoding
genes. For example, yeast STE6, encoding the a-fac-
tor mating peptide excreting ABC transporter, could
be complemented by the mouse mdr3 gene as well as
by the plasmodium pfmdr1 gene [80,81]. Moreover,
an amino acid substitution in TMS11 that a¡ected
the drug extrusion activity of Mdr3 also abolished its
ability to complement the yeast STE6 deletion. The
structure-function relationships of the separate do-
mains is described below.
3.1.2.1. The nucleotide binding domain. The nu-
cleotide binding domains of P-gp are composed of
the Walker A and B motifs, involved in the binding
and hydrolysis of ATP [82], and the ABC signature
which is typical of ABC transporters [48] (Fig. 4).
Drug dependent ATP hydrolysis [83^86] and ATP
dependent drug transport by P-gp [33,87] clearly
demonstrate that the energy requirements for sub-
strate translocation by P-gp are provided by ATP
[88,89]. For P-gp, it has been shown that both nu-
cleotide binding domains are essential for transport
and do not function independently as catalytic sites
[90,91]. Since the ATP binding domain is strongly
conserved among ABC transporters with various
speci¢cities, it is not expected that this domain is
involved in initial substrate recognition. As a conse-
quence, identi¢cation of an ABC-type nucleotide
binding domain alone cannot be taken as evidence
for a putative MDR transporter [92^94]. It should be
stressed that alterations in the drug resistance pro¢le
have been observed as a result of mutations in the
nucleotide binding domain, which indicate an inti-
mate relationship with the hydrophobic domain(s)
[95].
3.1.2.2. The transmembrane domain. Among the
ABC transporters the transmembrane domains are
less well conserved than the nucleotide binding do-
mains, which has been taken as an indication that
the initial substrate binding must take place in or
near the transmembrane domain. Photoa¤nity label-
ling experiments and mutant analysis have been used
to identify essential residues and putative drug bind-
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ing site(s) in P-gp [96]. Characterization of vinblas-
tine and azidopine photoa¤nity labelling of P-gp,
coupled to tryptic digestion and peptide analysis,
showed that both halves of the transporter are in-
volved in drug binding [97]. Extensive mutant anal-
ysis has indicated that substitutions in the predicted
TMSs 4, 5, 6, 10, 11, and 12 are associated with
altered drug resistance and drug extrusion pro¢les,
as well as with the reversal of photoa¤nity labelling
(Fig. 3) [90,98,99]. These ¢ndings suggest that both
halves of P-gp, and in particular the last three puta-
tive helices of each domain, contribute to the trans-
port pathway [69,97]. Additional regions that are
believed to participate in the transport mechanism
are the extracellular loop between TMS11 and 12
[100] and the ¢rst cytoplasmic loop between TMS2
and 3 [101].
Comparison of di¡erent P-gp homologs revealed a
higher degree of conservation of aromatic than non-
aromatic amino acids; the overall content of aro-
matic amino acids in MDR transporters is relatively
high compared to other transport proteins [102].
Molecular modelling of predicted transmembrane
K-helices with two or more appropriately spaced ar-
omatic rings revealed a putative transport pathway
in which the side chains of aromatic amino acids can
participate in the initial binding and subsequent
transport of typical MDR substrates like rhodamine
123 [102]. Indeed, quaternary ammonium com-
pounds can interact with tyrosine, phenylalanine or
tryptophan via electrostatic interactions with the
negatively charged quadrupole moment of the aro-
matic rings, formed by the Z-electrons [103].
3.2. Secondary drug transporters
In addition to ATP dependent transport, many
bacterial transport processes can be driven by the
electrochemical proton gradient or proton motive
force (vp) that is generated by energy transducing
enzymes located in the inner (cytoplasmic) mem-
brane. The vp is composed of an electrical potential
(vi ; interior negative) and a chemical proton gra-
dient (vpH; interior alkaline). Based on the structur-
al homology of secondary drug transporters with
known vp dependent transport proteins and the sen-
sitivity of drug transport to agents that selectively
dissipate the vi, it is generally assumed that these
transporters mediate extrusion of drug molecules in
exchange with protons. Direct involvement of the vp
FEMSRE 593 31-10-97
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12 LmrP L. lactis [105]
Bmr B. subtilis [46]
Blt B. subtilis [118]
NorA S. aureus [10]
14 QacA S. aureus [45,124]
QacB S. aureus [124]
EmrB E. coli [47]
LfrA M. smegmatis [114,115]
RND
c
12 AcrB E. coli [127]
AcrE E. coli [128]
MexB P. aeruginosa [130]
MexD P. aeruginosa [133]
MexF P. aeruginosa [132]
MtrD N. gonnorhoeae [113]
SMR
d
4 QacC/Smr S. aureus [111]
QacE K. pneumoniae [110]
EmrE E. coli [106]
10 TehA E. coli [134]
a
Predicted number of transmembrane segments.
b
Major facilitator superfamily [108].
c
resistance-nodulation-cell division family [109].
d
Small multidrug resistance family [112].
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as driving force in drug extrusion was demonstrated
for the tetracycline resistance determinant TetA,







) complex for one
proton [38,104]. Recent experiments, performed
with the lactococcal MDR transporter LmrP,
showed the involvement of both vpH and vi as a
driving force in drug extrusion which is in accord-
ance with an electrogenic drug/nH

(nv 2) antiport
reaction [105]. A similar mechanism was proposed
for the secondary multidrug transporters, EmrE
and Smr [106,107], and is most likely also involved
in other SDR and MDR transporters.
The secondary drug transporters comprise the
largest group of known drug extrusion systems in
bacteria, some of which are involved in multidrug
resistance, whereas others mediate e¥ux with a
high speci¢city. On the basis of similarities in size
and secondary structure, the secondary drug trans-
porters can be subdivided into three groups, i.e.
members of the drug resistance branch of the
major facilitator superfamily (MFS) of transporters
[108], the resistance, nodulation and cell division
(RND) family of membrane proteins [109], and the
family of small multidrug resistance (Smr) transport-
ers (Table 1) ([110^112], for a recent review on the
classi¢cation of secondary drug transporters, see
Paulsen et al. [113]). Some characteristic features of
these families will be discussed below.
3.2.1. The major facilitator superfamily
Members belonging to the MFS family of drug
transporters consist of either 12 or 14 putative
TMSs and are frequently found in bacteria
[108,113^115], but also in higher organisms like the
12 TMS members of the mammalian vesicular
neurotransmitter transporters (VNTs) [116]. The
VNTs catalyze the uptake of monoamines and ace-
tylcholine in synaptic vesicles but also confer re-
sistance to N-methyl-4-phenylpyridinium (MPP

)
[116,117]. The MDR transporters Bmr and Blt
from B. subtilis [46,118], NorA from S. aureus [10]
and LmrP from L. lactis [105] share extensive se-
quence and structural similarity with the well-char-
acterized SDR transporter TetA [38,111]. The sec-
ondary structure, as derived from the hydropathy
pro¢le combined with the positive inside rule [119],
most likely consists of 12 putative TMSs, with the
amino- and carboxy-termini and a large central do-
main located in the cytoplasm (Fig. 5). Analysis of
the primary sequences revealed signi¢cant similarity
between the carboxyl- and amino-terminal halves of
these proteins, suggesting that they might have
evolved from a duplication of a common ancestor
[24,120].
Within the primary sequences of these proteins,
two strongly conserved sequence motifs are recog-
nized [110]. Motif A (GxxxD(R/K)xGR(K/R)) is
present in most members of the MFS family in the
cytoplasmic loop between TMS2 and 3 and, in a
degenerated form, between TMS8 and 9 [120]
(Figs. 5 and 6). Motif B (GpilGPvlGG), also known
as the drug extrusion consensus motif, is found at
the end of TMS5 and is typical for the drug trans-
porters among the MFS family [121] (Figs. 5 and 6).
Functional analysis of site directed mutants in di¡er-
ent MFS transporters revealed the importance of
motif A for the transport function [120,122,123].
Since motif A is conserved in various transport pro-
teins, including antiporters as well as symporters
with di¡erent substrate speci¢cities, it is probably
not critical for substrate recognition. On the basis
of activity assays of mutant proteins, it has been
suggested that motif A is of structural importance
by mediating conformational changes essential for
opening and closing of the translocation pathway
[123]. Motif B, which is only found in the drug ex-
truding transporters of the MFS family, has been
suggested to be involved in the initial binding of
drugs and/or in determining the direction of sub-
strate transport [3,110]. However, experimental
data are not yet available to support these hypo-
theses. Since the secondary and ATP dependent
MDR transporters are able to transport identical
substrates it is tempting to look for similarities be-
tween these groups of transporters. However, struc-
tural features at the amino acid level between sec-
ondary MDR transporters and the ATP dependent
MDR transporters are even more di¤cult to dissect.
An exception could be the highly conserved motif
`WxLTLxxxxxxP' between TMS3 and TMS4 of the
ATP dependent MDR transporters (Fig. 4). This
motif is present in a somewhat degenerated form,
but at a similar position, in TMS10 of the secondary
MDR transporter LmrP (Fig. 5). However, only the
proline residue of this motif is found in other sec-
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ondary MDR transporters. Interestingly, the corre-
sponding proline residue in P-gp was found to be
essential for determining its drug speci¢city [90].
A recent study showed the importance of an acidic
residue in TMS10 of the 14 TMS MDR transporters
QacA and QacB in conferring resistance to divalent
cations [124]. Interestingly, Paulsen et al. [124] also
pointed to the presence of proline residues in TMS10
of QacA and QacB and their putative involvement in
conformational changes of the transport protein dur-
ing the transport process. The 14 TMS member,
EmrB of E. coli, forms an exceptional case in the
MFS family since its role in conferring resistance
to compounds like CCCP and thiolactomycin is
strictly coupled to an accessory protein, EmrA
[47,125]. It was speculated that EmrA and an addi-
tional outer membrane protein are essential to allow
drugs, transported over the cytoplasmic membrane
by EmrB, to traverse the periplasmic space and the
outer membrane into the extracellular space (see also
below) [3,47,126].
3.2.2. The RND family
Members of the RND family consist of 12 puta-
tive TMSs and are unrelated to the MFS family
(Table 1). RND proteins are mainly found in
Gram-negative bacteria, in which, after the initial
outward translocation of solutes across the cytoplas-
mic membrane, additional proteins are needed to
allow the drug to traverse the periplasm as well as
the outer membrane. In analogy to the MFS multi-
drug transporter complex EmrB/A, RND proteins
are probably connected to a periplasmic lipoprotein,
the so called membrane fusion proteins (MFP),
which in their turn in some cases are believed to
form a complex with outer membrane proteins.
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Fig. 5. Structural organization of bacterial secondary drug transporters. The transmembrane K-helical segments are indicated as ellipses.
The carboxy- (C) and amino-termini (N) and the large central loop (CL) are located in the cytoplasm. The conserved amino acid se-
quence motifs in the ¢rst cytoplasmic loop and in the ¢fth transmembrane segment are indicated by their primary sequences.
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Examples of RND/MFP complexes are: in E. coli,
AcrB/AcrA, a stress induced e¥ux pump [127], and
AcrE/AcrF (formerly known as EnvD/EnvC), which
is probably involved in cell division [128,129], and in
P. aeruginosa MexB/MexA, MexD/MexC plus the
recently discovered MexE/MexF complex, which
confer resistance to chloramphenicol, quinolones
and tetracycline [130^132]. The MexB/MexA system
was initially depicted as an e¥ux pathway for the
iron chelating siderophore pyoverdine, but is more
likely involved in the extrusion of secondary metab-
olites as proposed for the MexE/MexF complex
[131,132]. MexAB, MexCD and MexEF are encoded
by an operon which also encodes the OprM, OprJ
and OprN proteins that belong to a family of outer
membrane proteins [120,133]. Taken together these
observations strongly support the hypothesis that
MFPs and outer membrane proteins enable trans-
port across the outer membrane of Gram-negative
cells. RND proteins found in Gram-positive bacteria
are not associated with MFP proteins [113].
3.2.3. The small multidrug resistance (SMR) family
The SMR family of drug transporters are func-
tionally similar to the above mentioned secondary
MDR transporters but are generally much smaller
in size. These proteins, which are not homologous
to the MFS and RND transporters, are typically
around 110 amino acid residues in length and con-
tain four putative transmembrane K-helices. How-
ever, it was recently shown that the 36 kDa large
MDR transporter TehA of E. coli shares extensive
homology with the SMR family of drug transporters
in four out of the 10 predicted transmembrane
K-helices [134].
The small size of the SMR family members o¡ers
the advantage that residues and structural features
important for the drug/proton antiport mechanism
may be identi¢ed more easily than in the larger sec-
ondary drug transporters. Several amino acids in the
SMR members, QacC and Smr, have been impli-
cated, directly or indirectly, in substrate recognition
or the proper folding of the protein [106,111,
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Fig. 6. Alignment of the deduced amino acid sequences of the MDR transporters LmrP of L. lactis (LLLmrP), Blt and Bmr of B. subtilis
(BSBlt and BSBmr), and NorA of S. aureus (SANorA). The best alignment was obtained after hydropathy pro¢ling and by introducing
gaps in the putative loop regions. Putative transmembrane spanning K-helical segments are boxed and shown in bold-face. The conserved
motifs are shown below the alignment in bold-face.
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112,135]. Among these are the conserved glutamate
residues in Smr; i.e. Glu-13, the only charged residue
within a putative TMS, Glu-24 and Glu-80 which are
located in the ¢rst and second periplasmic loop, re-
spectively. Substitution of Glu-13 by an aspartate
residue abolished the e¥ux activity of Smr but also
a¡ected the expression level (24% of wild-type activ-
ity) [106]. Substitution of the Glu-24 and Glu-80
residues by aspartate did not a¡ect the expression
level but gave an increased resistance to ethidium.
Two highly conserved aromatic residues, Tyr-59
and Trp-62, located in TMS3, were also found to
be essential for the proper functioning or folding of
the transport protein [111]. These residues have been
proposed to be directly involved in the interaction
with the hydrophobic regions of the substrates, anal-
ogous to the proposed role of aromatic residues in
the function of P-gp [102,112]. In the light of this
hypothesis, attention should be paid to the role of
the aromatic residues in TMS2 at positions 40, 44
and 45, which are conserved in the MDR members
of the SMR family but are absent in structurally
related but functionally unrelated members of this
family. The precise roles of these residues, as well
as the question whether the SMR transporters func-
tion as monomers or oligomers, remain to be estab-
lished.
4. Regulation of drug resistance
The short-term exposure of cells to varying stress
conditions requires the well-controlled regulation of
gene expression. The expression of drug extrusion
systems is often induced by the drugs themselves;
the drugs serve as ligands, e¡ector molecules, of reg-
ulatory proteins. These regulatory proteins comprise
repressor proteins, which prevent gene transcription
through binding to so-called operator sites in the
promoter region, and activator proteins, which in-
duce transcription upon binding to the promoter re-
gion. Most of the genes specifying regulatory pro-
teins are transcribed divergently from the genes
that they regulate, using overlapping promoter re-
gions such that their own expression can be regu-
lated as well [136]. The best studied regulatory pro-
tein of drug transport is the tetracycline repressor
TetR [136,137]. The crystal structure of the TetR/
Tc-Mg

complex was recently solved with a resolu-
tion of 2.5 A
î
[138], which allowed the identi¢cation
of the substrate binding pocket within the TetR ho-
modimer. This study provides the ¢rst structural in-
formation on binding of a moderately hydrophobic
drug to a protein, which may have resemblance to
the binding of the Tc-Mg

complex to the TetA
transporter molecule. The only aromatic residue
that is directly involved in the binding of the Tc-
Mg

complex is the highly conserved Phe-86 residue,
which forms an unusual aromatic hydrogen bond
between the Z-electrons of the phenyl side chain
and a ^OH group of the Tc molecule. Mg
2
is coor-
dinated by two chelating ketoenolate groups of Tc
and three water molecules, two of which form hydro-
gen bonds to the carboxylate oxygen atoms of a Glu
residue. TetR binds with its two helix-turn-helix mo-
tifs to two operator regions in the promoter regions
of tetA and tetR, thereby blocking their expression.
Upon binding of Tc-Mg

, a conformational change
takes place which results in the release of the TetR/
Tc-Mg

complex from the DNA and the ability of
RNA polymerase to initiate transcription.
Similar repressor proteins are involved in the reg-
ulation of other drug transporters. For example,
TcmR negatively regulates the expression of the tet-
racenomycin C resistance gene tcmA of Streptomyces
glaucescens [14]. The repressor proteins AcrR and
MexR of E. coli regulate the expression of the
RND/MFP proteins AcrAB and MexAB, respec-
tively, and in addition regulate their own expression
[127,130]. In contrast to the above mentioned re-
pressor proteins, the negative regulator of the Em-
rAB complex, EmrR, is unidirectionally transcribed
with emrAB and encompasses no known DNA bind-
ing motifs [139]. The mechanism by which EmrR
regulates gene expression or whether EmrR binds
multiple drugs are not known but may involve addi-
tional regulatory proteins such as MarA and MarB
that are essential for the MDR phenotype of E. coli,
induced by the negative regulator and homolog of
EmrR, MarR (see below).
Activator proteins function as positive regulators
that enhance gene transcription. For instance the
homologous activators BmrR and BltR of B. subtilis
regulate the expression of the MDR transporters
Bmr and Blt, respectively [118]. Blt and Bmr share
51% sequence identity and extrude a similar spec-
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trum of drugs, i.e. ethidium bromide, rhodamine,
TPP

, doxorubicin, £uoroquinolone antibiotics and
acridine dyes. Interestingly, Blt and Bmr are di¡er-
entially regulated in response to the presence of
drugs. For example, rhodamine, which is a substrate
of both transporters, only induces Bmr. In accord-
ance with this observation, the DNA binding do-
mains of BmrR and BltR are related but the putative
drug binding domains are di¡erent. It has been sug-
gested that di¡erential regulation of Blt and Bmr
re£ects independent functions, involving the trans-
port of distinct physiological compounds [118]. Al-
ternatively, the identical substrate spectrum might
indicate that Bmr and Blt have a comparable func-
tion but that for example Blt is only expressed when
the `drug stress' is high, whereas the expression of
Bmr is switched on at a lower drug concentration
and/or with a larger variety of drugs. The direct in-
teraction of BmrR with structurally unrelated drugs,
i.e. rhodamine and TPP

, suggests, in analogy to the
variety of drugs that are recognized by MDR trans-
porters, a similar low speci¢city substrate binding
site [140]. Therefore, these multidrug binding pro-
teins may become useful model systems for the phe-
nomenon of MDR, at least as long as the transporter
molecules remain refractory towards structural (crys-
tallographic) analysis.
In addition to the speci¢c regulatory mechanisms
that a¡ect the expression of single multidrug e¥ux
systems, the MDR phenotype in bacteria can also
result from global regulatory mechanisms that a¡ect
the expression of (di¡erent) drug extrusion systems
as well as of other proteins involved in the intrinsic
resistance of the cell. The expression of the global
multiple antibiotic resistance (mar) operon of E. coli
[141,142] and various other bacteria [143^145] is in-
duced by weak acids such as salicylate, uncouplers
[146], but also by antibiotics like chloramphenicol
and tetracycline [147]. Expression of the marRAB
operon is negatively controlled by the regulator
MarR [148,149]. MarA appears to be a global pos-
itive regulator that is su¤cient to confer multiple
antibiotic resistance [141]. The function of MarB is
unknown, but it might be involved in the chloram-
phenicol and tetracycline mediated induction of the
MDR phenotype; these antibiotics do not bind to
MarR [150]. MarRAB a¡ects distant chromosomal
genes encoding proteins as diverse as outer mem-
brane porins (e.g. OmpF) [151], drug extrusion sys-
tems, including the AcrAB MDR e¥ux system [152],
but also proteins involved in superoxide resistance
(Fig. 7). Interestingly, a number of these genes are
also a¡ected by the superoxide stress response genes
soxRS [151,153]. MarA and the structural homolog
SoxS function as putative transcriptional activators
of a common group of promoters, thereby triggering
the expression of similar genes in response to di¡er-
ent environmental signals.
An increase in (multi-)drug resistance often occurs
after prolonged exposure to cytotoxic drugs and may
involve gene ampli¢cation and/or genetic changes ei-
ther in the structural gene or in regulatory compo-
nents of the MDR systems. Analogous to the over-
expression of P-gp in human cells, bacterial drug
resistance can result from the ampli¢cation of a
chromosomal encoded gene as is the case for the
bacillus MDR transporter Bmr [46], or from an in-
creased copy number of plasmid encoded genes [121].
In addition, drug resistance can result from speci¢c
mutations in the promoter or coding region of reg-
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Fig. 7. Multiple antibiotic resistance (Mar) and superoxide stress
response (Sox) regulation of gene expression in E. coli. Regula-
tion of expression of antibiotic and superoxide resistance and of
other genes involves the Mar and Sox pathway (according to
Rosner and Slonczewski [151]).
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ulatory proteins [9,60,143,147,154]. Although this
has not yet been established, drug resistance might
also result from mutations in the coding region of
structural genes, thereby a¡ecting the substrate a¤n-
ity and/or overall activity of the transport proteins.
5. The role of MDR transporters in drug extrusion
MDR not only poses a clinical problem, it also
raises the exciting scienti¢c question of how MDR
transporters can bind and extrude such a broad
range of structurally and functionally unrelated com-
pounds, since in general enzymes are quite speci¢c
for a few structurally closely related substrates.
A number of models have been postulated to ex-
plain the limited substrate speci¢city of MDR trans-
porters. The di¡erent models were initially based on
observations made for P-gp or MDR cell lines in
which the nature of the drug extrusion activity is
not well de¢ned. More recently, the models have
been extended to both primary and secondary
MDR transporters in bacteria [155,156]. The func-
tional similarity and the overlap in substrate `speci-
¢city' of di¡erent types of MDR transporters suggest
a universal mode of action of these transporters. In
the following section the major models are discussed.
5.1. Direct versus indirect drug transport
Although it seems evident that MDR of tumor
cells is caused by a lowered cytosolic drug concen-
tration due to P-gp expression, it had to be estab-
lished whether P-gp is directly involved in the extru-
sion of multiple drugs or whether MDR is an
indirect e¡ect of P-gp expression. Several observa-
tions are in accordance with a direct involvement
of P-gp and homologs in conferring MDR. (i) Direct
binding of drugs was shown by radiolabelling of
P-gp with photoactive analogs of typical MDR sub-
strates and reversing agents like vinblastine, dauno-
rubicin, colchicine, verapamil, azidopine, etc.
[96,99,157]. (ii) Binding and/or transport of drugs
by the MDR transporter stimulates ATP hydrolysis.
For example, vinblastine, colchicine and daunomycin
stimulate the ATPase activity of partially puri¢ed
and reconstituted human P-gp [84], hamster P-gp
[158], and of human P-gp expressed in insect cells
[83,86]. (iii) The drug speci¢city pro¢le of P-gp can
be altered by single amino acid substitutions which
cannot easily be explained by an indirect mechanism
[95,98].
An indirect role for P-gp was suggested, because
MDR tumor cells as well as cells transfected with
P-gp have, in general, a higher internal pH (pH
in
)
and a lower membrane potential (vi) than control
cells. As a direct consequence of a reduced vi, the
accumulation of lipophilic cations will be decreased.
An alkaline pH
in
will lower the accumulation of
weak bases such as the MDR substrates doxorubicin
and vinblastine, and might also a¡ect the binding of
drugs to its intracellular targets (e.g. colchicine bind-
ing to K-tubulin) [159,160]. Since this `passive trap-
ping' model does not require direct binding of drugs
to transport proteins, it can explain the apparent
lack in substrate speci¢city. In accordance with this
model, which has recently been reviewed [161], is the
observation that in wild-type cells, cytoplasmic alka-
linization results in a decreased drug accumulation,
whereas agents that acidify the cytosol reverse the
MDR phenotype [162,163]. P-gp might in£uence
the pH
in
or the vi by functioning as a chloride
channel [164] or as an electrogenic anion exchanger
or co-transporter [165].
Several observations, however, are in apparent
con£ict with a role of P-gp via an e¡ect on the vp.
(i) Several MDR cell lines have been characterized
that exhibit pH
in
values similar to those of control
cells [166^168]. (ii) Active drug extrusion in the pres-
ence of ionophores which dissipate the proton mo-
tive force has been observed in P-gp expressing
MDR cell lines [33,169] as well as membranes con-
taining other ATP dependent MDR transporters
[62,170].
In summary, the experimental data favor the di-
rect involvement of P-gp, and of its functional ana-
logs, in the binding and transport of multiple unre-
lated drugs. Although the indirect mechanism may in
some instances contribute to the drug resistant phe-
notype, it plays no critical role in the majority of
MDR cells.
6. Putative routes of drug binding and drug transport
The two extreme possible mechanisms of drug ex-
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trusion, i.e. those based on the acquisition of the
substrate from the cytoplasm versus those that envis-
age the cytoplasmic membrane as the site from
which drugs are removed, are discussed in the fol-
lowing section.
6.1. Drug extrusion from the cytoplasm
Conventional ideas about carrier mediated sub-
strate transport comprise the initial capturing (bind-
ing) of substrates from the aqueous phase, followed
by translocation across the lipid bilayer, release of
the substrate into the aqueous phase at the trans site
of the membrane, and reorientation of the empty
binding site(s) (Fig. 8; aqueous pore). E¤cient bind-
ing and transport of a wide diversity of substrates
will require a high £exibility of the putative substrate
binding site. Such a binding site should have proper-
ties similar to that found in, for example, albumin,
which binds di¡erent amphiphilic substances [3].
One main argument for drug pumping from the
cytoplasm is based on the assumption that the
pump rate at non-saturating conditions depends on
the substrate concentration at the site from which it
is expelled. This implies that extrusion of drugs from
the cytoplasm will a¡ect the e¥ux rate only, whereas
the passive rate of drug uptake will not be a¡ected.
On the other hand, drug pumping from the mem-
brane will result in an apparent decrease in the pas-
sive rate of drug uptake. At this stage it is important
to realize that determination of the initial transport
rates requires accurate methods with a high time
resolution since many substrates equilibrate rapidly
over the membrane. The observation that the initial
rate of rhodamine 123 uptake by P-gp expressing
cells does not signi¢cantly di¡er from that of the
wild-type strain was used as an argument in favor
of rhodamine extrusion from the cytoplasm [168].
However, initial in£ux rates were determined indi-
rectly, i.e. from the extent of £uorescence quenching
upon insertion of the drug into the mitochondrial
membrane. This method precludes an accurate and
fast analysis. An alternative method to measure ini-
tial drug transport rates was based on £uorescence
resonance energy transfer (FRET) between the drug
and a reporter molecule [171]. This study revealed
that the initial daunorubicin partitioning into the
membrane of P-gp expressing cells did not di¡er sig-
ni¢cantly from that of the parental strain, suggesting
that P-gp mediated drug extrusion might occur from
the cytoplasm. A major drawback of the use of dau-
norubicin in these experiments is the sensitivity of
the probe to local pH changes (the pKa of the free
amino group of daunomycin is 8.3). Consequently,
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Fig. 8. Putative routes of carrier mediated drug transport. Drugs can be expelled from the aqueous phase (aqueous pore model) or from
the membrane. The hydrophobic vacuum cleaner model predicts drug binding to the carrier protein from the inner or outer lea£et of the
phospholipid bilayer, followed by extrusion into the external medium. Alternatively, drugs can be £ipped from the inner to the outer
membrane lea£et after which they can di¡use into the external medium (£ippase model).
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the exact concentration of the positively charged
daunorubicin, the actual transported species, in the
membrane is unknown. Moreover, the slow transbi-
layer distribution of the charged species might be
overlooked because of the more rapid equilibration
of the neutral species, which will contribute most to
the initial FRET dependent £uorescence quenching.
The observation that daunorubicin is concentrated at
the interphase region between the inner lea£et and
the aqueous space, whereas the cytoplasmic concen-
tration is very low, makes it very unlikely that this
drug is e¤ciently transported from the cytoplasm
[172^174].
6.2. Drug extrusion from the membrane
Although MDR substrates can structurally be very
di¡erent, the physical properties shared by many of
the molecules include a high hydrophobicity, an am-
phiphilic nature and a net positive charge, although
neutral compounds, among which hydrophobic pep-
tides, have also been described as substrates of P-gp.
Due to their physical properties these compounds
will readily intercalate in the phospholipid bilayer
as was shown for several MDR substrates
[33,155,172]. On the basis of the preferential parti-
tioning of these molecules in the membrane, it has
been proposed that MDR transporters might bind
and actively remove hydrophobic drugs at the level
of the cell membrane [66]. This model suggests that a
possible physiological function of MDR transporters
includes maintenance of membrane integrity, which
is essential for the barrier function of the membrane.
MDR transporters would thus function as `hydro-
phobic vacuum cleaners', which transport drugs
from either the inner or the outer lea£et of the lipid
bilayer into the external medium (Fig. 8; hydropho-
bic vacuum cleaner) [96,175]. Alternatively, MDR
proteins might function as a `£ippase', a variation
on the `hydrophobic vacuum cleaner' model, by
translocating drugs from the inner to the outer mem-
brane lea£et after which the molecules will di¡use
into the external medium (Fig. 8; £ippase)
[176,177]. Although the £ippase model of Higgins
and Gottesman envisages pumping from the inner
to the outer lea£et as well as pumping directly into
the external space as possible mechanisms of P-gp
mediated drug extrusion, this name is confusing since
£ipping is usually associated with the transbilayer
movement of lipids (and not transfer into the me-
dium).
Several observations are in agreement with the hy-
pothesis of drug pumping from the membrane
although the experiments do not rigorously exclude
transport from the cytoplasm. (i) Fluorescent MDR
substrates like Hoechst 33342, which speci¢cally la-
bel the phospholipid bilayer, are actively extruded
from proteoliposomal membranes containing puri-
¢ed P-gp [32]. (ii) A close association of drugs with
the MDR transporters was concluded from photo-
a¤nity labelling experiments. Photoactivation of
photolabile membrane probes such as doxorubicin
and rhodamine 123 exclusively labelled P-gp, where-
as a broad range of membrane proteins were labelled
aspeci¢cally in the parental strain [96,97]. In addi-
tion, various substrates that partition in the mem-
brane were able to compete with the photoactive
drug analogs for binding to P-gp [178]. (iii) Doxo-
rubicin resistance was reversed by hydrophobic for-
skolins and not by a hydrophilic, water soluble for-
skolin analog, revealing that hydrophobicity is an
important determinant of P-gp speci¢city [179]. (iv)
Drug extrusion from the membrane was also con-
cluded from the decreased uptake of non-£uorescent
ester derivatives like BCECF-AM and calcein-AM in
P-gp expressing cells [180]. These acetoxymethyl es-
ters are readily hydrolyzed by intracellularly located
non-speci¢c esterases, resulting in the formation of
the £uorescent indicators. This allows the uptake of
the AM esters to be followed £uorimetrically.
Although the rate determining steps in these experi-
ments were not studied in detail, the observed P-gp
mediated £uorescence decrease is indicative of the
active extrusion of the AM derivatives from the
membrane, prior to hydrolysis in the cytoplasm. In
a similar experiment, using the lactococcal MDR
transporter LmrA, it was established that the passive
di¡usion of the AM ester over the membrane is the
rate determining step rather than the esterase activ-
ity, con¢rming the active extrusion of the AM deriv-
atives from the membrane [155]. (v) The reduced
initial uptake rate of colchicine and vinblastine by
P-gp expressing cells [181] and the reduced binding
of daunomycin to membranes of non-P-gp MDR
cells as determined by FRET [171] are also in favor
of drug extrusion from the membrane. These latter
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studies, however, are subject to the same type of
criticism as given in Section 6.1, i.e. low time reso-
lution and uncertainties about substrate concentra-
tions in the relevant cellular compartments (mem-
brane versus cytoplasm). (vi) Finally, the most
convincing evidence for drug pumping from the
membrane was derived from £uorescence studies of
the lactococcal MDR transporters, LmrA and LmrP,
using di¡erently charged derivatives of the highly
hydrophobic £uorescent membrane probe diphenyl-
hexatriene (DPH) [155,156]. It could be shown that
both LmrA and LmrP extrude the cationic DPH
derivative 1-[4-(trimethylamino)phenyl]-6-phenylhex-
a-1,3,5-triene (TMA-DPH) directly from the inner
lea£et of the lipid bilayer into the external medium.
Like TMA-DPH (Fig. 9d), the cationic DPH deriv-
ative N-p-(6-phenyl-(1,3,5-hexatrienyl(phenyl-(pro-
pyl))))trimethylammonium (TMAP-DPH) (Fig. 9e)
is also transported by these drug extrusion systems.
However, the neutral 1-[4-(dimethylamino)phenyl]-6-
phenylhexa-1,3,5-triene (DMA-DPH) (Fig. 9b) and
DPH (Fig. 9a), or the anionic 1,6-diphenylhexa-
1,3,5-triene carboxylic acid (CA-DPH) (Fig. 9c) are
not extruded. Fig. 9 shows a graphic representation
of the iso-electrostatic potential surfaces of the
various DPH derivatives as calculated by a semi-
empirical quantum chemical method. The red and
blue regions map out areas which are electron rich
and poor, respectively. The data show that the pre-
ferred substrates are strongly amphiphilic and planar
with a positively charged area and a large dipole
moment. The ionized group will stabilize and con-
centrate these molecules at the membrane-water in-
terface. Although the anionic CA-DPH has similar
physicochemical properties, its negative charge seems
not to be compatible with the drug transporters. Due
to its charge, the vi (inside negative) in intact cells
will prevent it from accumulating at the water-lipid
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Fig. 9. Electrostatic potential isosurfaces of DPH (a), DMA-DPH (b), CA-DPH (c), TMA-DPH (d) and TMAP-DPH (e). Electronic
structures were calculated after a semi-empirical geometry optimization using the AM1 force ¢eld in hexadecane as solvent. Calculations
were performed on a Silicon Graphics Indigo2 equipped with a R4400/200 processor using the SPARTAN 4.1.1. (Wavefunction Inc.,
Irvine, CA) software package. The values of the electrostatic potential are transparently color coded onto the van der Waals contact sur-
face indicating the accessible regions on the molecules which are electron rich (red) and electron poor (blue). The molecules are shown as
a stick model. The calculated dipole moments (in Debye) are: DPH, 0; DMA-DPH, 1.5; CA-DPH, 31.8; TMA-DPH, 24.2; and TMAP-
DPH, 34.9.
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interface of the inner membrane lea£et. This is the
site from which the drugs are extruded by the LmrA
and LmrP proteins [155,156]. It should be empha-
sized that the strong polarized charge distribution
as observed for TMA(P)-DPH is not immediately
evident for all of the multidrug extrusion substrates.
Although the more complex substrates such as ethi-
dium and daunomycin are fairly amphiphilic, this is
not evident for substrates like BCECF-AM or TPP

.
In addition, these experiments clearly show that hy-
drophobicity alone is not of crucial importance. For
example, the calculated partition coe¤cient of the
not transported compound DPH is ¢ve times higher
and therefore more hydrophobic than TMA-DPH.
Therefore, the lack of correlation between the hydro-
phobicity of di¡erent £uoroquinolones and NorA
mediated resistance against these compounds [182]
is not necessarily in con£ict with the hydrophobic
vacuum cleaner model. In contrast, the observed cor-
relation between NorA mediated resistance and the
bulkiness of one side group and the hydrophobicity
of another side group of the £uoroquinolones tested
might point to charge distributions and amphiphilic-
ity that favor the intercalation at the water-lipid in-
terface of the lipid bilayer as suggested above. In
summary, the ability of amphiphilic substrates to
partition in the inner lea£et of the membrane is
probably the most important prerequisite for recog-
nition by multidrug transporters.
Substrate pumping from the membrane has also
been proposed as the mechanism of action for the
mouse ABC transporter Mdr2, which in contrast to
Mdr1 is not involved in drug resistance. Instead,
Mdr2 (mainly expressed in the canalicular membrane
of the liver) mediates phospholipid excretion into
the bile [183]. The Mdr2 mediated transport of a
£uorescent phosphatidylcholine (PC) analog in yeast
secretory vesicles [184] and the P-gp mediated trans-
location of a wide variety of short chain lipids
[185] are therefore indicative of a £ippase-like mech-
anism, i.e. translocation of lipids from the inner to
the outer membrane lea£et [184]. Recognition of
substrates at the membrane level is probably also
an important feature of the ABC transporter HlyB
of E. coli. HlyB is involved in the excretion of the
K-hemolysin toxin HlyA across the cytoplasmic
membrane. The accessory proteins HlyD and the
outer membrane protein TolC are required to allow
HlyA to traverse the periplasmic space and the outer
membrane of the Gram-negative envelope [186,187].
HlyA has a carboxy-terminal signal sequence with
two K-helices which target the protein to the mem-
brane [188,189]. This signal sequence, which is un-
structured in an aqueous environment, forms stable
K-helical structures in the membrane independent of
HlyB and is critical for the translocation of HlyA
across the cell envelope [190]. Several suppressor
mutations in HlyB, which were able to correct for
defects in HlyA transport due to deletions in the
HlyA signal sequence, were found to be clustered
in the transmembrane spanning domain of HlyB.
This strongly suggest that HlyA interacts, through
its signal sequence, directly with the substrate bind-
ing pocket in the transmembrane domain of HlyB
[191].
6.3. Drug extrusion and transporter structure
The functional relationship and overlap in sub-
strate speci¢city between P-gp and other MDR
transporters of both pro- and eukaryotic origin sug-
gests a general mechanism of drug extrusion. As was
shown for the lactococcal secondary and primary
MDR transporters, LmrP and LmrA, substrate
binding at the cytoplasmic lea£et of the lipid bilayer
appears to be essential for substrate recognition by
the MDR transporters [155,156].
Substrate binding in the membrane requires the
lateral movement of substrates in the plane of the
membrane to the binding pocket. Higgins and Got-
tesman [176] proposed a global tertiary organization
of P-gp consisting of two blocks of six transmem-
brane segments that open sideways to allow sub-
strates to approach the protein from the membrane;
an approach of substrates from the aqueous phase
was not excluded (Fig. 10A). The initial substrate
binding is followed by the translocation and release
of the substrates at the trans side of the membrane, a
process that might be induced by an energy requiring
conformational change in the transport protein. Al-
ternatively, the substrate could enter the protein in a
`three times four' organization (Fig. 10B) similar to
the three-fold rotational symmetry that was observed
in the crystal structure of the 12 TMSs containing
subunit I of cytochrome c oxidase from Paracoccus
denitri¢cans [192]. This model would also agree with
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the proposed homotrimeric transmembrane organi-
zation of the SMR transporters [112]. Information
on the number of substrate binding sites and detailed
structural data at a high resolution will be required
to evaluate these models.
7. Physiological role of MDR transporters
Many speculations have been put forward about
the natural function of MDR transporters. The dis-
tribution of di¡erent P-gp isoforms may re£ect dif-
FEMSRE 593 31-10-97
Fig. 10. Model for the uptake of drugs from the membrane. Top view showing 12 transmembrane segments in a two time six (A) or a
three times four organization (B). The putative routes via which membrane associated substrates might gain access to the drug transporter
are indicated by arrows.
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Fig. 11. Hydrophobic vacuum cleaner model for the removal of hydrophobic drugs from the inner lea£et of the phospholipid bilayer.
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ferent transport functions in di¡erent tissues such
as the extrusion of endogenous peptides or poly-
peptides, which lack a classical `signal peptide'
[30,193,194], or the excretion of bile acids from the
liver into bile [34,195]. Functional complementation
of the yeast Ste6 protein by a mammalian MDR
transporter is in agreement with peptides as possible
physiological substrates [80]. However, a general de-
toxi¢cation mechanism against naturally occurring
hydrophobic xenotoxins is even more appealing.
These toxins can be ingested with food, originate
from endogenous metabolism such as the oxidation
of phospholipids, or can originate from parasitic
(bacterial, fungal or protozoal) infections. A similar,
general detoxi¢cation mechanism can be envisioned
for MDR in microorganisms, which encounter nu-
merous hydrophobic compounds in their natural en-
vironment (for a review on the membrane toxicity of
various lipophilic compounds see Sikkema et al.
[196]). Enteric bacteria like E. coli have to cope
with similar hydrophobic compounds, e.g. bile salts
and fatty acids, as encountered by mammalian cells
[127]. The high hydrophobicity of these compounds
results in their accumulation into lipid bilayers,
where they can exert their toxic e¡ects. Transferrin
conjugates of adriamycin may serve as an example in
this respect since these compounds are cytotoxic at
the membrane level without entering the cell [197].
The view of MDR transporters as `hydrophobic vac-
uum cleaners' (Fig. 11) is thus in accordance with
their broad substrate speci¢city, their proposed
mode of action as well as with their widespread dis-
tribution throughout the bacterial, plant and animal
kingdoms.
If drug transport from the inner to the outer lea£et
as suggested by the £ippase model is true, MDR
transporters might also have a role in maintaining
an asymmetric distribution of phospholipids in the
lipid bilayer [176]. An asymmetric lipid distribution
is essential since both membrane halves have di¡er-
ent functions [198]. The outer lea£et is in direct con-
tact with the extracellular environment, whereas the
inner lea£et provides the majority of sites for various
enzymatic functions [199^201]. In the light of this
feature, removing drugs from the inner lea£et will
be e¤cient, independent of whether drug are £ipped
to the outer lea£et or to the external medium. The
observation that mouse Mdr2, which is not involved
in drug extrusion, mediates the translocation of PC
is in accordance with the £ippase model [184]. A
similar observation was recently made for human
MDR3, a non-drug pumping P-gp homolog, which
speci¢cally translocates short chain PC [185]. In ad-
dition, van Helvoort et al. [185] were able to show
P-gp mediated translocation of a wide variety of
short chain lipid molecules across the plasma mem-
brane. Therefore, in addition to a function in remov-
ing xenotoxins from the membrane, which can
include naturally occurring toxic short chain phos-
pholipid fragments, MDR transporters might also be
involved in maintaining the membrane lipid organi-
zation. However, endogenous long chain phospho-
lipids that constitute the lipid bilayer are unlikely
to be transported by P-gp, since that would lead to
competition between drugs and the abundant phos-
pholipids for binding. Consequently, P-gp mediated
drug transport would be severely inhibited. This idea
is supported by the observation of Ruetz and Gross,
who were unable to show transport of PC by the
mouse MDR transporter Mdr3 [184] and by Smit
et al., who showed that mouse Mdr3 was unable to
compensate for the absence of mouse Mdr2 in trans-
porting PC into the bile of an mdr2 knock-out mouse
[183].
A more de¢ned function has been proposed for
MRP in the glutathione S-transferase dependent de-
toxi¢cation pathway for electrophilic drugs [202].
MRP mediates the ATP dependent export of leuko-
triene C4 and related anionic glutathione conjugates,
but also of cationic drugs like anthracyclines and
vinca alkaloids [34,203]. Although the MRP medi-
ated transport of cationic drugs like vincristine and
daunomycin is enhanced by glutathione, there is no
indication that these compounds are conjugated be-
fore translocation [204]. The exact role of gluta-
thione remains to be established.
8. Concluding remarks
Several questions related to the mechanism of
MDR transporters remain to be answered. For ex-
ample: what is the role of P-gp in the proposed Cl
3
channel activity? Which amino acid residues are in-
volved in substrate binding? What is the common
feature in the substrates recognized by MDR trans-
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porters? Answers to these question may be generated
by the structure-function analysis of mutant pro-
teins, but will ultimately require high resolution
structures of the proteins. The overproduction and
generation of mutants require good expression sys-
tems, which makes the mammalian cell systems less
suitable than yeast or bacteria. However, heterolo-
gous expression of the mammalian MDR transport-
ers in bacteria or yeast may lead to other obstacles
such as toxicity of ampli¢ed membrane proteins, the
instability of proteins due to the presence of host
proteases, the lack of protein modi¢cation (phos-
phorylation and/or glycosylation) [69], and others.
Indeed, the attempts to amplify P-gp in E. coli
have so far yielded moderate expression levels
[205], and possibly an altered topology of the puta-
tive TMSs [72]. A better model system might be pro-
vided by prokaryotic functional and/or structural
P-gp homologs like LmrA and LmrP, which can
easily be expressed in E. coli or other prokaryotes
[155,156].
In the last decade, the potentially disastrous con-
sequences of drug resistance in bacteria to public
health were substantiated by several incidents. Hos-
pital departments and operation rooms had to be
disinfected and closed for prolonged periods due to
the occurrence of (multi-)drug resistant pathogenic
bacteria. In addition, ever more cases of the out-
break of, for example, tuberculosis were reported
in well-developed western countries. Signi¢cant prog-
ress has been made towards our knowledge of the
various mechanisms underlying MDR. However, it
has not yet led to an adequate answer to the treat-
ment of these infections. Although drug resistance
mediated by MDR transporters cannot be seen as
the major cause of clinical MDR, the increasing
number of multidrug transporters that are identi¢ed
shows that e¥ux mediated MDR must not be re-
garded as a exceptional phenomenon but rather as
a defence mechanism which is conserved throughout
life. Hopefully, our increasing knowledge of the
mechanisms underlying MDR will eventually lead
to the rational design of drugs that are not recog-
nized by the various MDR systems, or drugs that are
able to inhibit these systems, allowing the more tra-
ditional chemotherapeutics to do their work. In ad-
dition, one might think of alternative therapies
which are aimed at the prevention rather than the
treatment of the diseases, or at improving our natu-
ral defence mechanism (the immune system). Perhaps
we may even have to live with the versatile organ-
isms and shift our attention from strategies to elim-
inate the organisms to strategies which eliminate
their toxic e¡ects.
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